Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor A Randomized, Double-blind, Placebo-controlled, Cross Over Explorative Study

Currently, there is no medication available to adequately treat patients undergoing hemodialysis who are suffering from intradialytic hypotension (IDH). Medical interventions such as Trendelenburg positioning, saline bolus administration, reduction of ultrafiltration rate, interruption of the hemodialysis, and other medical treatments are the methods of choice to treat the hypotensive condition of these patients and thus to maintain the systolic blood pressure. Patients suffering from IDH have a higher reported mortality rate due to the given stress on their cardiovascular system. New treatments, therefore, would give clinicians an additional alternative to current existing approaches and might help patients to maintain their blood pressure during hemodialysis.
The main objective of the study is to evaluate the efficacy of icatibant in the prevention of systolic blood pressure (SBP) drop in patients on hemodialysis suffering from recurrent IDH episodes during hemodialysis.

开始日期2023-12-11

申办/合作机构

Vanderbilt University Medical Center

[+2]

NCT05509569 / RecruitingN/A

Specified Drug Use Surveillance of FIRAZYR Subcutaneous Injection 30mg Syringe for Pediatric Subjects With Hereditary Angioedema (All-Case Investigation)

This study is a survey in Japan of Icatibant subcutaneous injection 30 mg syringe used to treat children or teenagers with acute attacks of hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effects related from Icatibant subcutaneous injection 30 mg syringe and to check if Icatibant subcutaneous injection 30 mg syringe improves acute attacks of HAE.
During the study, pediatric participants with HAE will take Icatibant subcutaneous injection 30mg syringe according to their clinic's standard practice. The study doctors will check for side effects from Icatibant subcutaneous injection 30 mg syringe for 3 months.

开始日期2022-08-24

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT05407597 / Completed临床2/3期

Prospective, Randomised, Double-blind Trial of Icatibant Compared to Placebo in Patients With Early Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infection

There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.

开始日期2022-05-16

申办/合作机构

Belfast Health & Social Care Trust

[+1]

100 项与醋酸艾替班特相关的临床结果

登录后查看更多信息

100 项与醋酸艾替班特相关的转化医学

登录后查看更多信息

100 项与醋酸艾替班特相关的专利（医药）

登录后查看更多信息

1,578

项与醋酸艾替班特相关的文献（医药）

2024-02-09·Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Hereditary angioedema with normal C1-Inhibitor: Clinical and genetic characterization of 15 Portuguese unrelated families.

Article

作者: Eunice Dias de Castro ; Ana Luísa Pinhal ; Mariana Bragança ; João Parente Freixo ; António Martinho

BACKGROUND:

Hereditary angioedema with normal C1-INH (HAE-nC1-INH) is a rare genetic disease with similar phenotype to HAE-C1-INH, but different genetic background. Currently six subtypes are recognized, based on the underlying mutations. Several aspects need further clarification.

OBJECTIVE:

To assess clinical features of patients with genetically characterized HAE-nC1-INH, from the North of Portugal.

METHODS:

Retrospective assessment of clinical data from all patients with HAE-nC1-INH followed at a HAE Reference Center.

RESULTS:

Forty-one patients were identified, four with no family history. The FXII-mutation Thr328Lys (38 carriers) was the most prevalent. Three new potentially disease causing variants linked to HAE-nC1-INH were identified (c.529+4A>G:FXII; Cys248*:Kininogen-1; Arg261His:Plasminogen). The HAE-FXII cohort included 82% females and 71.8% symptomatic patients. Penetrance rate was significantly higher in females (81.3% vs 28.6; p=0.012). A hormonal influence was observed in 96.2% of the symptomatic females, although 62.5% remained symptomatic after oral estrogens withdrawal. Trauma and dental procedures were frequent triggers (82.6% and 45.5%, respectively). Main locations were facial (described by 96%), lips (82.1%) and eyelids (64.3%). One patient reported erythema marginatum as prodrome. Plasma derived C1-INH was effective as short-term prophylaxis in all treated patients, but only in 80% as on demand treatment. Icatibant was effectively used on demand in 9 patients, but with relapses in five (57%).

CONCLUSION:

We described the first Portuguese series of patients with HAE-nC1-INH genetically characterized. Differences with others may contribute to improve current unmet needs and raise awareness of this rare disease. We highlight the identification of 3 new variants(additional molecular studies are ongoing) and the first report of erythema marginatum in HAE-n-C1INH.

2023-12-28·European journal of neurology

Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase-induced orolingual angioedema.

Article

作者: Aikaterini Theodorou ; Evangelia-Makrina Dimitriadou ; Dimitrios Tzanetakos ; Eleni Bakola ; Maria Chondrogianni ; Lina Palaiodimou ; Anna Keramida ; Sofia Vassilopoulou ; Michael Makris ; Georgios P Paraskevas ; Georgios Tsivgoulis

BACKGROUND AND PURPOSE:

Orolingual angioedema (OA) represents a rare but life-threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase-induced OA who have failed to respond to first-line therapies including corticosteroids, antihistamines, and/or adrenaline.

METHODS:

We present a patient with alteplase-induced OA who showed substantial clinical improvement following the administration of icatibant.

RESULTS:

We describe a 71-year-old woman with known arterial hypertension under treatment with angiotensin-converting enzyme inhibitor, who presented with acute ischemic stroke in the territory of the right middle cerebral artery and received intravenous alteplase. During intravenous thrombolysis, the case was complicated with OA without any response to standard anaphylactic treatment including corticosteroids, dimetindene, and adrenaline. Thirty minutes after symptom onset, icatibant, a synthetic selective bradykinin B2-receptor antagonist, was administered subcutaneously. Substantial symptomatic resolution was observed only following the icatibant administration.

CONCLUSIONS:

This case highlights the effectiveness of icatibant in the acute management of alteplase-induced OA. In particular, icatibant administration, following first-line therapies including corticosteroids, antihistamines, and/or adrenaline, may avert tracheostomy and intubation in resistant and refractory cases with OA following intravenous thrombolysis for acute ischemic stroke.

2023-12-22·European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant.

Article

作者: Giulia Mazzoccanti ; Simone Manetto ; Michele Bassan ; Marco Macis ; Walter Cabri ; Alessia Ciogli ; Antonio Ricci ; Francesco Gasparrini

The biopharmaceutical industry faces the challenge of efficiently characterising impurity profiles of therapeutical peptides, also due to their complex polar and ionisable attributes. This research explores the potential of advanced chromatographic techniques to address this challenge. The study compares dynamic electrostatic repulsion reversed phase (d-ERRP) to its counterparts (static ERRP and ion pair reversed phase IP-RP) in analysing Icatibant and its elusive epimeric impurity, [L-Arg]¹-Icatibant and highlights its exceptional capabilities in generating symmetric peaks, mitigating the common tailing phenomenon, and serving as a steadfast guardian of column longevity. The result highlights d-ERRP as a pioneering tool in the domain of liquid chromatography, fostering its role as a reference technique for the analysis of therapeutic peptides.

项与醋酸艾替班特相关的新闻（医药）

2024-02-27

·Business Wire

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC. The following presentations occurred at AAAAI 2024: Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation) Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation) Despite their perception of treating attacks “early”, many patients did not meet guideline recommendations for prompt on-demand treatment after recognition of an HAE attack The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation) Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation) Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks One-third of patients using icatibant did not treat or delayed treatment due to anxiety about refills Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation) People living with HAE understood the importance of treating HAE attacks early and recognized that earlier treatment translates to quicker recovery and resolution Delayed on-demand treatment (> 1 hour) lengthened the time to “feeling in control” of an attack and the time to feeling fully recovered The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation) People with HAE needed to make adjustments to their daily lives including avoiding situations where their injectable on-demand treatment may be discovered by others Embarrassment associated with carrying on-demand treatment was among the reasons HAE patients delayed administration of on-demand treatment Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation) Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times Nearly half of patients on LTP patients experienced moderate to extreme levels of anxiety when anticipating on-demand treatment administration Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation) Almost one third of people with HAE experienced the return of an HAE attack requiring ≥1 additional dose of on-demand treatment HAE attacks treated within 1 hour returned less frequently compared with attacks treated after ≥1 hour “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments. The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.” Links to all posters and presentations can be found on the KalVista website under “Publications”. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista disclosed positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024. The Company anticipates submitting a new drug application to the U.S. FDA for sebetralstat in the first half of 2024 and expects to file for approval in Europe and Japan later in 2024. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases. For more information about KalVista, please visit www.kalvista.com . Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including the KONFIDENT-S trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

临床3期临床结果

2024-02-13

·BioPharmaDive

Kalvista pill succeeds in late-stage study for rare swelling disorder

Dive Brief:An experimental pill developed by KalVista Pharmaceuticals succeeded in a Phase 3 trial, giving the drug a chance to become the first oral on-demand treatment for people with the rare swelling disorder hereditary angioedema.In a statement Tuesday, KalVista said the drug, sebetralstat, met the studys main and secondary goals, reducing the severity of swelling attacks significantly faster than did a placebo. Participants on sebetralstat first felt relief from symptoms a median of 1.6 hours after receiving a low dose and 1.8 hours after a high dose, within range of available, injectable medicines.KalVista also said, without offering specifics, that the drug had a safety profile similar to placebo. No serious treatment-related adverse events occurred, and no patients left the trial because of side effects. The company plans to file for U.S. approval in the first half of 2024 and later this year in Europe and Japan.Dive Insight:Though hereditary angioedema, or HAE, is a rare condition estimated to affect one in 50,000 people globally, the disease has become a crowded area of drug research.Multiple medicines exist to either treat or prevent the diseases hallmark swelling attacks, which can last for days if untreated and affect a variety of organs. All are limited in some way, however. Acute treatments such as Takedas Firazyr and Pharming Groups Ruconest can require several injections each episode. Preventive options, like BioCryst Pharmaceuticals Orladeyo, reduce the rates of attacks, but dont ward them off entirely.Those drawbacks have left room for improvement, and several drugmakers have stepped in to try to fill the gap. CSL, Ionis Pharmaceuticals and Intellia Therapeutics are developing longer-lasting preventive therapies, while Kalvista and rival Pharvaris are advancing pills to treat swelling episodes as effectively as injectable drugs.Mid-stage study results reported in 2021 and published in The Lancet last year indicated Kalvistas drug might fulfill that promise, with symptom relief occurring between 1.5 to 2 hours. That finding made the companys Phase 3 study, a larger trial, closely watched by analysts and investors. Shares climbed by about one-third this year in anticipation.While KalVista only disclosed summary findings in its press release Tuesday, they suggest the drug has met analysts expectations. The median time to symptom relief observed is close to what was reported in testing of Ruconest and Firazyr, and within a bull case previously outlined by Leerink Partners analyst Joseph Schwartz.In a recent survey of 44 HAE specialists, analysts at the investment bank Jefferies reported that specialists want an oral drug that could relieve symptoms sooner than 2.5 hours. A quarter of those surveyed said theyd switch their patients to Kalvistas drug if it proved as effective as Firazyr.Jefferies analyst Maury Raycroft has estimated the drug can generate about half of a billion dollars in peak yearly sales in the U.S. and Europe.We set a high bar for an oral therapy to deliver on the efficacy that is seen with approved injectable products, while also improving on the side-effect profile and treatment burden associated with injectables, said CEO Andrew Crockett, in an email to BioPharma Dive. These Phase 3 data delivered on that promise, and in many ways surpassed it.Still, the company didnt share details that could help determine its competitive positioning versus injectable drugs as well as Pharvaris rival treatment. Among them are more granular details on the size and speed of its effects.Detailed results will be presented at a medical meeting later this month. '

临床3期临床结果

2024-01-22

·MedCity News

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is now preparing to submit its drug candidate for FDA review. However, the key data that will determine how competitive the drug could be won’t become available until later this year. The Ionis drug, donidalorsen, is in development for hereditary angioedema (HAE), an inherited disease that leads to swelling attacks throughout the body. When these attacks close off the airway, they can become life threatening. Ionis reported Monday that its subcutaneously injected drug met the main trial goal of reducing the rate of angioedema attacks dosed every four weeks or every eight weeks compared to a placebo. The drug was well tolerated by patients and no serious adverse events were reported in the treatment group, according to the Carlsbad, California-based company. Ionis did not provide additional details about donidalorsen’s safety or the reduction in HAE attacks, but said it plans to present the Phase 3 results at an upcoming medical meeting this year. In Phase 2 testing, the average reduction in HAE attacks compared to a placebo was 90% in weeks one to 17. Furthermore, Phase 2 results showed 92% of treated patients were attack free versus 0% in the placebo arm from weeks five to 17. “We are very pleased with the positive topline results from the Phase 3 OASIS-HAE study of donidalorsen,” Kenneth Newman, senior vice president, head of clinical development at Ionis, said in a prepared statement. “Based on these results and the durable efficacy and favorable safety data seen in the ongoing Phase 2 open-label extension study, we believe donidalorsen, if approved, could be an attractive new treatment option for patients with HAE, many of whom continue to experience unpredictable, painful and severe breakthrough attacks despite currently available prophylactic treatments.” Ionis’s drugs are based on antisense oligonucleotides, small pieces of DNA or RNA that bind to messenger RNA to stop the production of a disease-causing protein. Donidalorsen is designed to target the mRNA responsible for producing a protein called prekallikrein, a precursor to the kallikrein protein that contributes to HAE attacks. If Ionis can bring its HAE drug to the market, it would compete against Takeda Pharmaceutical’s Kalbitor, an injectable kallikrein inhibitor. Another Takeda HAE drug, Firazyr, blocks a different protein called bradykinin. BioCryst Pharmaceuticals has commercialized an oral kallikrein inhibitor branded as Orladeyo. KalVista Pharmaceuticals has reached Phase 3 testing with sebetralstat, an oral kallikrein inhibitor developed as an on-demand treatment for HAE attacks. KalVista expects to report preliminary Phase 3 data early this year. Ionis said the scientific meeting presentation of donidalorsen’s Phase 3 data will happen by mid-2024. That’s also the time frame for reporting results from the open-label extension of the Phase 3 test and the separate group of patients who have transitioned to the Ionis drug from another prophylactic. These are the key data that will determine how the Ionis drug could match up against the competition. In a note sent to investors Monday, Leerink Partners analyst Mani Foroohar wrote that these results will clarify whether donidalorsen’s commercial profile supports broad switching from other drugs or if it will be driven mainly by newly diagnosed patients. Ionis plans to handle U.S. commercialization of donidalorsen if it’s approved. European commercialization is in the hands of Otsuka Pharmaceutical. In December, Ionis struck a deal granting Otsuka those rights in exchange for a $65 million upfront payment. The deal makes Otuska responsible for European regulatory submissions. The Japanese drugmaker would owe Ionis milestone payments and royalties from its sales of the drug in Europe. Image by Getty Images

临床3期临床结果临床2期引进/卖出

100 项与醋酸艾替班特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04492	醋酸艾替班特	B06AC02	DB06196

研发状态

适应症	最高研发状态	国家/地区	公司
遗传性血管性水肿	批准上市	欧盟更多	Accord Healthcare SLU 更多
I型和II型遗传性血管性水肿	批准上市	列支敦士登更多	Takeda Pharmaceuticals International AG 更多
骨关节炎	终止	德国更多	Sanofi SA 更多
肌肉骨骼疼痛	终止	欧盟更多	Hoechst Pakistan Ltd. 更多
血管性水肿	终止	加拿大更多	Shire Plc 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00500656 (FAST-2, Pubmed \| J Allergy Clin Immunol)	临床3期	遗传性血管性水肿	85	Icatibant	範鏇願壓網獵願窪窪糧(窪膚構糧遞簾鏇鑰構艱) = 觸遞構積餘遞簾衊蓋網鑰廠鬱鑰選範製製鹽構 (築壓淵觸醖觸壓觸膚簾 )	积极	2013-11-01
NCT01386658 (Pubmed \| J Allergy Clin Immunol Pract) 人工标引	临床3期	遗传性血管性水肿	32	Icatibant	網齋淵齋遞艱遞鬱壓構(繭鹹齋艱衊齋選艱鹽鹹) = 鹽積蓋壓膚憲積顧願齋鬱壓糧範鏇鏇襯齋選築 (淵鏇積製齋繭襯窪憲齋 ) 更多	积极	2017-11-01
ARVO2013	N/A	-	-	Compound 1 (CMPD-1)	艱選鬱窪製遞積衊製艱(淵憲選憲鏇製淵遞鑰鑰) = 夢淵蓋廠製積淵鬱蓋願廠蓋廠顧簾觸壓鹽鏇糧 (蓋窪鬱鏇鹹襯鹹遞蓋選 ) 更多	-	2013-06-01
ARVO2013	N/A	-	-	Bradykinin (BK)	艱選鬱窪製遞積衊製艱(淵憲選憲鏇製淵遞鑰鑰) = 衊廠獵觸積鬱淵襯觸鬱廠蓋廠顧簾觸壓鹽鏇糧 (蓋窪鬱鏇鹹襯鹹遞蓋選 ) 更多	-	2013-06-01
NCT04978051 (ICAT·COVID, Pubmed)	临床2期	新型冠状病毒感染	73	Icatibant + standard care	(顧艱淵簾範壓廠觸鏇遞) = 襯憲醖繭製蓋築鏇選壓鑰齋築鏇鬱範衊觸鏇淵 (遞鹽繭網醖蓋憲憲獵築 ) 更多	积极	2023-01-04
NCT04978051 (ICAT·COVID, Pubmed)	临床2期	新型冠状病毒感染	73	icatibant (Standard care alone)	(顧艱淵簾範壓廠觸鏇遞) = 鬱築構蓋壓觸憲鹹鏇餘鑰齋築鏇鬱範衊觸鏇淵 (遞鹽繭網醖蓋憲憲獵築 ) 更多	积极	2023-01-04
NCT01034969 (Pubmed \| Ann Allergy Asthma Immunol)	N/A	遗传性血管性水肿 C1 inhibitor deficiency	633	Icatibant	鬱製網積鏇網齋襯繭構(鬱鹽醖鹹糧獵窪餘觸鹽) = 壓積膚膚願構遞餘願觸醖淵積構簾遞觸窪襯鏇 (蓋製積糧膚獵鑰淵壓積 ) 更多	-	2016-10-01
NCT03888755 (Pubmed \| Allergol Int) 人工标引	临床3期	遗传性血管性水肿	8	icatibant	夢餘衊鹹壓鏇網夢願鏇(獵衊顧積窪鏇遞網鑰鏇) = 製鑰鏇願襯襯範餘壓衊襯糧鑰餘鏇淵襯獵醖網 (鏇簾積鹹選願憲餘醖醖, 1.00 ~ 2.50)	积极	2020-04-01
NCT01154361 (Pubmed \| Br Dent J) 人工标引	临床2期	血管性水肿	27	icatibant	顧築構構繭壓蓋鏇齋夢(範齋淵襯膚糧艱壓醖醖) = 廠蓋鬱窪構繭齋餘築築衊製壓築壓構窪選襯衊 (鑰廠鹹淵網願範選範鏇, 3.0 ~ 16.0) 更多	积极	2015-01-29
NCT01154361 (Pubmed \| Br Dent J) 人工标引	临床2期	血管性水肿	27	prednisolone+clemastine	顧築構構繭壓蓋鏇齋夢(範齋淵襯膚糧艱壓醖醖) = 襯壓範鹽選醖淵窪積衊衊製壓築壓構窪選襯衊 (鑰廠鹹淵網願範選範鏇, 20.3 ~ 48.0) 更多	积极	2015-01-29
NCT00912093 \| NCT01034969 (FAST-3, IOS, Pubmed \| Allergy Asthma Proc)	临床3期	遗传性血管性水肿	-	Icatibant	鏇網醖繭憲觸艱獵艱襯(製構網製獵簾積齋積餘) = 夢廠構廠鏇鏇築壓齋獵鹹壓淵衊夢積蓋鹽製襯 (醖醖鑰鏇構鬱鹹餘顧選 ) 更多	-	2014-10-31
NCT00912093 (FAST-3, Pubmed \| Int Arch Allergy Immunol)	临床3期	遗传性血管性水肿	98	Icatibant 30 mg	膚願蓋積製蓋積窪構鬱(鬱獵繭鏇鏇積獵鬱醖夢) = 鹽網鏇積鏇積蓋遞簾夢襯憲築遞網醖餘積繭觸 (鑰鏇簾壓構餘築襯鬱構 ) 更多	积极	2015-01-01
NCT00912093 (FAST-3, Pubmed \| Int Arch Allergy Immunol)	临床3期	遗传性血管性水肿	98	Placebo	膚願蓋積製蓋積窪構鬱(鬱獵繭鏇鏇積獵鬱醖夢) = 糧夢觸襯鹹鏇壓糧簾膚襯憲築遞網醖餘積繭觸 (鑰鏇簾壓構餘築襯鬱構 ) 更多	积极	2015-01-01
NCT00997204 (Pubmed \| J Allergy Clin Immunol)	临床3期	遗传性血管性水肿	151	Self-administered icatibant	憲鑰鏇艱齋糧淵鏇衊壓(構觸顧窪築醖夢鹹窪壓) = Recurrence or worsening of HAE symptoms (22 of 97) was the most commonly reported AE 製餘選鑰製築糧壓簾鹽 (廠遞糧選願廠獵餘鹹夢 ) 更多	-	2014-03-01